• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 13F-HR filed by Takeda Pharmaceutical Company Limited

    8/7/25 8:51:50 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    SEC FORM 13F-HR

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 13F

    FORM 13F COVER PAGE

    OMB APPROVAL
    OMB Number: 3235-0006
    Estimated average burden
    hours per response: 23.8

    Report for the Calendar Year or Quarter Ended: 06-30-2025
    Check here if Amendment    Amendment Number:
    This Amendment (Check only one.):    is a restatement.
       adds new holdings entries.
    Institutional Investment Manager Filing this Report:
    Name: TAKEDA PHARMACEUTICAL CO LTD
    Address: 1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku
    Tokyo, M0  103-8668
    Form 13F File Number: 028-24938
    CRD Number (if applicable):
    SEC File Number (if applicable):

    The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

    Person Signing this Report on Behalf of Reporting Manager:
    Name: Amit Singh
    Title: Senior Vice President and Head of Treasury
    Phone: 81-3-3278-2111
    Signature, Place, and Date of Signing:
    /s/Amit Singh Tokyo,  M0 08-07-2025
    [Signature] [City, State] [Date]
    Report Type (Check only one.):
    X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
       13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
       13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
    Form 13F Summary Page
    Report Summary:
    Number of Other Included Managers: 1
    Form 13F Information Table Entry Total: 12
    Form 13F Information Table Value Total: 19,553,783
    (round to nearest dollar)
    List of Other Included Managers:
    Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
    [If there are no entries in this list, state “NONE” and omit the column headings and list entries.]
    No. Name Form 13F File No. CRD No. (if applicable) SEC File No. (if applicable) CIK
    1 Takeda Vaccines, Inc. 028-24939      

    Get the next $TAK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

    Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Reflecting Generic Erosion Reported Operating Profit Increase of 11.0% at AER, Reflecting Lower YoY Impairment and Restructuring Expenses Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1 Reinforce Continued Momentum in Late-Stage Pipeline No Change to Full-Year Outlook Announced in May Takeda ((4502, NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended Jun

    7/30/25 2:41:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

    HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA1 First Devices Customized for a Plasma-Derived Therapy in Takeda's Broad and Differentiated Portfolio Reflect Company's Commitment to Providing a Patient-Centric Ecosystem of Support Created With Input from Patients and Caregivers to Help Improve In-Home Infusion Takeda ((TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, devices for patients 17 years of age and older that allow HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] to be transferred from vials without using a needle in a home environme

    7/21/25 8:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

    – Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results – Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile – Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible – These Results Mark a Major Advancement Toward Transforming the Standard of Care by Addressing the Underlying Cause of Narcolepsy Type 1 Takeda ((TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-cont

    7/14/25 3:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Vatroslav Mateljic Appointed General Manager of Takeda Canada

    Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry.  Mos

    9/16/24 8:39:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

    Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave

    3/26/24 7:07:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

    2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre

    12/5/23 8:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

    3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

    5/9/22 6:10:39 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

    3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

    4/29/22 6:02:17 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

    3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

    10/21/21 8:40:37 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    SEC Filings

    View All

    SEC Form 13F-HR filed by Takeda Pharmaceutical Company Limited

    13F-HR - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    8/7/25 8:51:50 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/31/25 6:03:33 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/30/25 6:02:51 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Takeda Pharma upgraded by Morgan Stanley

    Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

    4/2/25 8:46:19 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00

    3/16/23 7:24:52 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Pharma upgraded by Cowen with a new price target

    Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously

    7/19/22 7:32:25 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Financials

    Live finance-specific insights

    View All

    Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

    Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Reflecting Generic Erosion Reported Operating Profit Increase of 11.0% at AER, Reflecting Lower YoY Impairment and Restructuring Expenses Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1 Reinforce Continued Momentum in Late-Stage Pipeline No Change to Full-Year Outlook Announced in May Takeda ((4502, NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended Jun

    7/30/25 2:41:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

    Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

    6/1/25 8:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

    Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

    5/8/25 2:36:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/6/24 9:36:34 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/5/24 6:24:58 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/7/23 2:10:49 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care